{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:11:12Z","timestamp":1771042272798,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non\u2010alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress. However, the pathophysiology of NAFLD in type 2 diabetes with hyperlipidaemia is not fully known, as well as the utility of the commonly prescribed anti\u2010diabetic and lipid\u2010lowering drugs in ameliorating liver injury markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Hepatic complications of type 2 diabetes with hyperlipidaemia and the effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were tested using genetic type 2 diabetic Goto\u2013Kakizaki rats fed with a high\u2010fat diet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The high\u2010fat diet aggravated the overall metabolic state and the hepatic markers of injury. All treatments decreased fasting glycaemia, insulin resistance and free fatty acid levels. Combined treatment further decreased C\u2010reactive protein (CRP), adiponectin, liver tumour necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) and interleukin\u20106 (IL\u20106), systemic and hepatic oxidative stress and portal inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data provides evidence of a greater benefit with a combination of atorvastatin and metformin in improving liver injury in type 2 diabetes with hyperlipidaemia. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/dmrr.1157","type":"journal-article","created":{"date-parts":[[2010,11,6]],"date-time":"2010-11-06T00:19:55Z","timestamp":1289002795000},"page":"54-62","source":"Crossref","is-referenced-by-count":56,"title":["Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia"],"prefix":"10.1002","volume":"27","author":[{"given":"P.","family":"Matafome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Louro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cris\u00f3stomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sei\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1682-x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00755-3"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802502"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890510037383"},{"key":"e_1_2_7_7_2","first-page":"547","article-title":"Adipose tissue: a regulator of inflammation","volume":"19","author":"Juge\u2010Aubry C","year":"2005","journal-title":"J Clin Endoc Metab"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2006.12.006"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M600120-MCP200"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0022-2275(20)30035-3","article-title":"Attenuation of plasma low density lipoprotein cholesterol by select 3\u2010hydroxy\u20103\u2010methylglutaryl coenzyme A reductase inhibitors inmice devoid of low density lipoprotein receptors","volume":"38","author":"Bisgaier C","year":"1997","journal-title":"J Lipid Res"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000202706.70992.95"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0381"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.04.009"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2007.06.005"},{"key":"e_1_2_7_15_2","first-page":"42","article-title":"Defici\u00eancia prim\u00e1ria da secre\u00e7\u00e3o de insulina de ilh\u00e9us isolados de ratos Goto\u2010Kakizaki, um modelo animal de diabetes tipo 2 n\u00e3o obesa","volume":"17","author":"Sei\u00e7a RM","year":"2004","journal-title":"Acta Med Port"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-007-0252-8"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.1914"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.08.064"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.07.047"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2450"},{"key":"e_1_2_7_21_2","first-page":"1010","article-title":"The effects of different doses of atorvastatin on plasma endothelin\u20101 levels in type 2 diabetic patients with dyslipidemia","volume":"231","author":"Lam H","year":"2006","journal-title":"Exp Bio Med"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.05.009"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2008.04945.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.2092"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345565"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/157339906777950651"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00624.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2007.03.018"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.30.23"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2006.11.007"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.02.024"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03412.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016110792006879"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.013"},{"key":"e_1_2_7_35_2","first-page":"39","article-title":"Therapeutic options in non\u2010alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study","volume":"16","author":"Georgescu E","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02926.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-008-0032-0"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0827"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.1157","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.1157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T19:18:48Z","timestamp":1696792728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.1157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1002\/dmrr.1157"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.1157","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}